vs
Side-by-side financial comparison of AGIOS PHARMACEUTICALS, INC. (AGIO) and HARTE HANKS INC (HHS). Click either name above to swap in a different company.
HARTE HANKS INC is the larger business by last-quarter revenue ($39.9M vs $20.0M, roughly 2.0× AGIOS PHARMACEUTICALS, INC.). HARTE HANKS INC runs the higher net margin — 5.5% vs -541.1%, a 546.6% gap on every dollar of revenue. On growth, AGIOS PHARMACEUTICALS, INC. posted the faster year-over-year revenue change (86.1% vs -15.4%). HARTE HANKS INC produced more free cash flow last quarter ($-686.0K vs $-97.3M). Over the past eight quarters, AGIOS PHARMACEUTICALS, INC.'s revenue compounded faster (56.1% CAGR vs -6.4%).
Agios Pharmaceuticals Inc. is a publicly trading American pharmaceutical company pioneering therapies for genetically defined diseases, with a near-term focus on developing therapies for hemolytic anemias. The company was founded in 2008 by Lewis Cantley, Tak Mak and Craig Thompson. Agios is a Delaware corporation headquartered in Cambridge, Massachusetts. The company tendered an initial public offering in July 2013.
Harte Hanks is a global marketing services company headquartered in Boston, Massachusetts. Harte Hanks services include analytics, strategy, marketing technology, creative services, digital marketing, customer care, direct mail, logistics, and fulfillment.
AGIO vs HHS — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $20.0M | $39.9M |
| Net Profit | $-108.0M | $2.2M |
| Gross Margin | 90.6% | — |
| Operating Margin | -608.9% | -0.3% |
| Net Margin | -541.1% | 5.5% |
| Revenue YoY | 86.1% | -15.4% |
| Net Profit YoY | -11.9% | — |
| EPS (diluted) | $-1.86 | $0.30 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $20.0M | $39.9M | ||
| Q3 25 | $12.9M | $39.5M | ||
| Q2 25 | $12.5M | $38.6M | ||
| Q1 25 | $8.7M | $41.6M | ||
| Q4 24 | $10.7M | $47.1M | ||
| Q3 24 | $9.0M | $47.6M | ||
| Q2 24 | $8.6M | $45.0M | ||
| Q1 24 | $8.2M | $45.4M |
| Q4 25 | $-108.0M | $2.2M | ||
| Q3 25 | $-103.4M | $-2.3M | ||
| Q2 25 | $-112.0M | $-335.0K | ||
| Q1 25 | $-89.3M | $-392.0K | ||
| Q4 24 | $-96.5M | — | ||
| Q3 24 | $947.9M | $142.0K | ||
| Q2 24 | $-96.1M | $-27.8M | ||
| Q1 24 | $-81.5M | $-171.0K |
| Q4 25 | 90.6% | — | ||
| Q3 25 | 87.0% | — | ||
| Q2 25 | 86.3% | — | ||
| Q1 25 | 87.6% | — | ||
| Q4 24 | 88.3% | — | ||
| Q3 24 | 91.3% | — | ||
| Q2 24 | 82.6% | — | ||
| Q1 24 | 92.3% | — |
| Q4 25 | -608.9% | -0.3% | ||
| Q3 25 | -907.4% | 1.3% | ||
| Q2 25 | -1020.1% | 0.1% | ||
| Q1 25 | -1222.0% | -0.1% | ||
| Q4 24 | -1165.3% | -3.3% | ||
| Q3 24 | -1146.9% | 4.0% | ||
| Q2 24 | -1228.3% | 3.0% | ||
| Q1 24 | -1124.3% | 0.8% |
| Q4 25 | -541.1% | 5.5% | ||
| Q3 25 | -803.1% | -5.8% | ||
| Q2 25 | -899.4% | -0.9% | ||
| Q1 25 | -1023.3% | -0.9% | ||
| Q4 24 | -899.6% | — | ||
| Q3 24 | 10574.7% | 0.3% | ||
| Q2 24 | -1115.7% | -61.8% | ||
| Q1 24 | -995.8% | -0.4% |
| Q4 25 | $-1.86 | $0.30 | ||
| Q3 25 | $-1.78 | $-0.31 | ||
| Q2 25 | $-1.93 | $-0.05 | ||
| Q1 25 | $-1.55 | $-0.05 | ||
| Q4 24 | $-1.44 | $-0.31 | ||
| Q3 24 | $16.22 | $0.02 | ||
| Q2 24 | $-1.69 | $-3.84 | ||
| Q1 24 | $-1.45 | $-0.02 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $89.1M | $5.6M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $1.2B | $20.5M |
| Total Assets | $1.3B | $91.8M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $89.1M | $5.6M | ||
| Q3 25 | $92.7M | $6.5M | ||
| Q2 25 | $80.9M | $4.8M | ||
| Q1 25 | $79.0M | $9.0M | ||
| Q4 24 | $76.2M | $9.8M | ||
| Q3 24 | $253.7M | $5.9M | ||
| Q2 24 | $84.5M | $11.0M | ||
| Q1 24 | $118.8M | $11.5M |
| Q4 25 | $1.2B | $20.5M | ||
| Q3 25 | $1.3B | $19.9M | ||
| Q2 25 | $1.4B | $22.2M | ||
| Q1 25 | $1.5B | $21.4M | ||
| Q4 24 | $1.5B | $21.7M | ||
| Q3 24 | $1.6B | $21.0M | ||
| Q2 24 | $660.5M | $20.6M | ||
| Q1 24 | $743.9M | $20.0M |
| Q4 25 | $1.3B | $91.8M | ||
| Q3 25 | $1.4B | $92.7M | ||
| Q2 25 | $1.5B | $95.0M | ||
| Q1 25 | $1.6B | $100.6M | ||
| Q4 24 | $1.7B | $101.8M | ||
| Q3 24 | $1.8B | $108.1M | ||
| Q2 24 | $773.1M | $109.7M | ||
| Q1 24 | $849.7M | $113.4M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-96.2M | $737.0K |
| Free Cash FlowOCF − Capex | $-97.3M | $-686.0K |
| FCF MarginFCF / Revenue | -487.5% | -1.7% |
| Capex IntensityCapex / Revenue | 5.6% | 3.6% |
| Cash ConversionOCF / Net Profit | — | 0.33× |
| TTM Free Cash FlowTrailing 4 quarters | $-377.3M | $-4.5M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-96.2M | $737.0K | ||
| Q3 25 | $-88.2M | $3.2M | ||
| Q2 25 | $-77.1M | $-4.8M | ||
| Q1 25 | $-111.5M | $-818.0K | ||
| Q4 24 | $-133.2M | $4.0M | ||
| Q3 24 | $-84.2M | $-2.9M | ||
| Q2 24 | $-72.6M | $1.6M | ||
| Q1 24 | $-99.9M | $-5.7M |
| Q4 25 | $-97.3M | $-686.0K | ||
| Q3 25 | $-89.7M | $2.2M | ||
| Q2 25 | $-78.0M | $-5.1M | ||
| Q1 25 | $-112.3M | $-923.0K | ||
| Q4 24 | $-134.1M | $3.4M | ||
| Q3 24 | $-84.6M | $-4.9M | ||
| Q2 24 | $-72.7M | $926.0K | ||
| Q1 24 | $-100.0M | $-6.2M |
| Q4 25 | -487.5% | -1.7% | ||
| Q3 25 | -696.5% | 5.5% | ||
| Q2 25 | -626.2% | -13.1% | ||
| Q1 25 | -1286.4% | -2.2% | ||
| Q4 24 | -1250.1% | 7.3% | ||
| Q3 24 | -944.2% | -10.2% | ||
| Q2 24 | -844.4% | 2.1% | ||
| Q1 24 | -1221.2% | -13.7% |
| Q4 25 | 5.6% | 3.6% | ||
| Q3 25 | 12.1% | 2.5% | ||
| Q2 25 | 7.0% | 0.6% | ||
| Q1 25 | 8.8% | 0.3% | ||
| Q4 24 | 9.0% | 1.3% | ||
| Q3 24 | 4.7% | 4.0% | ||
| Q2 24 | 1.8% | 1.5% | ||
| Q1 24 | 1.7% | 1.2% |
| Q4 25 | — | 0.33× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | -0.09× | -20.76× | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AGIO
Segment breakdown not available.
HHS
| Fulfillment And Logistics Services | $17.3M | 43% |
| Customer Care | $13.7M | 34% |
| Other | $8.9M | 22% |
